AR117228A1 - DERIVADOS DE PIRAZOLO[1,2-a]PIRIDINA, 1H-BENZO[d][1,2,3]TRIAZOL, IMIDAZOPIRIMIDINA Y BENCIMIDAZOL PARA USAR EN EL TRATAMIENTO DE LA INFECCIÓN POR ARENAVIRUS - Google Patents
DERIVADOS DE PIRAZOLO[1,2-a]PIRIDINA, 1H-BENZO[d][1,2,3]TRIAZOL, IMIDAZOPIRIMIDINA Y BENCIMIDAZOL PARA USAR EN EL TRATAMIENTO DE LA INFECCIÓN POR ARENAVIRUSInfo
- Publication number
- AR117228A1 AR117228A1 ARP190103517A ARP190103517A AR117228A1 AR 117228 A1 AR117228 A1 AR 117228A1 AR P190103517 A ARP190103517 A AR P190103517A AR P190103517 A ARP190103517 A AR P190103517A AR 117228 A1 AR117228 A1 AR 117228A1
- Authority
- AR
- Argentina
- Prior art keywords
- independently selected
- alkyl
- nhr10
- halogen
- treatment
- Prior art date
Links
- 208000005989 Arenaviridae Infections Diseases 0.000 title abstract 2
- HYZJCKYKOHLVJF-UHFFFAOYSA-N 1H-benzimidazole Chemical compound C1=CC=C2NC=NC2=C1 HYZJCKYKOHLVJF-UHFFFAOYSA-N 0.000 title 1
- VNHBYKHXBCYPBJ-UHFFFAOYSA-N 5-ethynylimidazo[1,2-a]pyridine Chemical compound C#CC1=CC=CC2=NC=CN12 VNHBYKHXBCYPBJ-UHFFFAOYSA-N 0.000 title 1
- KDCGOANMDULRCW-UHFFFAOYSA-N 7H-purine Chemical compound N1=CNC2=NC=NC2=C1 KDCGOANMDULRCW-UHFFFAOYSA-N 0.000 title 1
- WTKZEGDFNFYCGP-UHFFFAOYSA-N Pyrazole Chemical class C=1C=NNC=1 WTKZEGDFNFYCGP-UHFFFAOYSA-N 0.000 title 1
- QRUDEWIWKLJBPS-UHFFFAOYSA-N benzotriazole Chemical compound C1=CC=C2N[N][N]C2=C1 QRUDEWIWKLJBPS-UHFFFAOYSA-N 0.000 title 1
- 125000004169 (C1-C6) alkyl group Chemical group 0.000 abstract 7
- 229910052805 deuterium Inorganic materials 0.000 abstract 6
- 229910052739 hydrogen Inorganic materials 0.000 abstract 6
- 229910052736 halogen Inorganic materials 0.000 abstract 5
- 150000002367 halogens Chemical class 0.000 abstract 5
- 125000000882 C2-C6 alkenyl group Chemical group 0.000 abstract 3
- 101100240516 Caenorhabditis elegans nhr-10 gene Proteins 0.000 abstract 3
- 150000001875 compounds Chemical class 0.000 abstract 2
- 241000712891 Arenavirus Species 0.000 abstract 1
- 125000003601 C2-C6 alkynyl group Chemical group 0.000 abstract 1
- 102000003886 Glycoproteins Human genes 0.000 abstract 1
- 108090000288 Glycoproteins Proteins 0.000 abstract 1
- 208000036142 Viral infection Diseases 0.000 abstract 1
- 239000003085 diluting agent Substances 0.000 abstract 1
- 239000003937 drug carrier Substances 0.000 abstract 1
- 150000002391 heterocyclic compounds Chemical class 0.000 abstract 1
- 230000001404 mediated effect Effects 0.000 abstract 1
- 150000003839 salts Chemical class 0.000 abstract 1
- 239000003981 vehicle Substances 0.000 abstract 1
- 230000009385 viral infection Effects 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/4164—1,3-Diazoles
- A61K31/4184—1,3-Diazoles condensed with carbocyclic rings, e.g. benzimidazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/4192—1,2,3-Triazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
- A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D235/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings
- C07D235/02—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings condensed with carbocyclic rings or ring systems
- C07D235/04—Benzimidazoles; Hydrogenated benzimidazoles
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D235/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings
- C07D235/02—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings condensed with carbocyclic rings or ring systems
- C07D235/04—Benzimidazoles; Hydrogenated benzimidazoles
- C07D235/06—Benzimidazoles; Hydrogenated benzimidazoles with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached in position 2
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D249/00—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms
- C07D249/16—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms condensed with carbocyclic rings or ring systems
- C07D249/18—Benzotriazoles
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems
Landscapes
- Chemical & Material Sciences (AREA)
- Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Epidemiology (AREA)
- Virology (AREA)
- Oncology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Communicable Diseases (AREA)
- Molecular Biology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
Abstract
Compuestos heterocíclicos utilizables en el tratamiento de infecciones por arenavirus e infecciones víricas mediadas por glicoproteínas de arenavirus. Reivindicación 1: Un compuesto de fórmula estructural (1), o una sal farmacéuticamente aceptable y un portador, diluyente o vehículo farmacéuticamente aceptable del mismo, en donde A se selecciona independientemente entre C y N; G se selecciona independientemente entre CH, CD y N; E se selecciona independientemente entre CH, CD y N; J se selecciona independientemente entre los restos de fórmula (2) y (3); R² se selecciona independientemente entre H, D, -OR³, -R⁴, -NHR¹⁰, -CONHR¹⁰; R³ se selecciona independientemente entre H, D, alquilo C₁₋₆, alquenilo C₂₋₆, -NHC(O)R⁴, -C(O)NHR¹⁰ y -C(O)R¹⁰, en donde cada alquilo C₁₋₆ está opcionalmente sustituido con D, halógeno, -OH, -OR⁴, -NHR¹⁰; R⁴ se selecciona independientemente entre alquilo C₁₋₆ y cicloheteroalquilo C₂₋₉ opcionalmente sustituido con D, halógeno, -OH, -OR¹⁰ y NHR¹⁰; R⁵ se selecciona independientemente entre H, D, alquilo C₁₋₆, alquenilo C₂₋₆, alquinilo C₂₋₆, halógeno, -OR³, -CO₂R¹⁰, -NHC(O)R⁴, -C(O)NHR¹⁰, -NHR¹⁰, -CHNHR¹⁰, -CN, -CR⁴ y -C(O)R¹⁰, en donde cada alquilo C₁₋₆ está opcionalmente sustituido con D; R⁶ se selecciona independientemente entre H, D, halógeno, -OR³ y R⁴; R⁹ se selecciona independientemente entre H, D, halógeno, -OR¹⁰ y alquilo C₁₋₆; R¹⁰ se selecciona independientemente entre H, D, -OH, alquilo C₁₋₆ y alquenilo C₂₋₆; y cuando E es N, CH o CD, entonces A es C, G es CH o CD y J es el resto de fórmula (2); y cuando A es N, entonces J es el resto de fórmula (3); con la condición de que se excluyan los compuestos: seleccionados del grupo de fórmulas (4).
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201862776390P | 2018-12-06 | 2018-12-06 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| AR117228A1 true AR117228A1 (es) | 2021-07-21 |
Family
ID=70975517
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ARP190103517A AR117228A1 (es) | 2018-12-06 | 2019-12-02 | DERIVADOS DE PIRAZOLO[1,2-a]PIRIDINA, 1H-BENZO[d][1,2,3]TRIAZOL, IMIDAZOPIRIMIDINA Y BENCIMIDAZOL PARA USAR EN EL TRATAMIENTO DE LA INFECCIÓN POR ARENAVIRUS |
Country Status (10)
| Country | Link |
|---|---|
| EP (1) | EP3890731A4 (es) |
| JP (1) | JP7675009B2 (es) |
| KR (1) | KR20210106997A (es) |
| CN (1) | CN113329750B (es) |
| AR (1) | AR117228A1 (es) |
| AU (1) | AU2019393784B2 (es) |
| BR (1) | BR112021010909A2 (es) |
| EA (1) | EA202191001A1 (es) |
| MX (2) | MX2021005234A (es) |
| WO (1) | WO2020117794A1 (es) |
Families Citing this family (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN116217490B (zh) * | 2023-02-03 | 2025-09-26 | 中国人民解放军军事科学院军事医学研究院 | 一种苯并咪唑类化合物及其制备方法和应用 |
| EP4434972A1 (en) * | 2023-03-22 | 2024-09-25 | Eberhard-Karls-Universität Tübingen | Atm kinase inhibitors |
| WO2025137345A1 (en) * | 2023-12-20 | 2025-06-26 | Arisan Therapeutics Inc. | Crystalline forms of an imidazopyridine derivative |
Family Cites Families (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO1995026325A2 (en) * | 1994-03-25 | 1995-10-05 | Isotechnika Inc. | Enhancement of the efficacy of drugs by deuteration |
| WO2012065297A1 (en) * | 2010-11-16 | 2012-05-24 | Impact Therapeutics, Inc. | 3-ARYL-6-ARYL-[1,2,4]TRIAZOLO[4,3-a]PYRIDINES AS INHIBITORS OF CELL PROLIFERATION AND THE USE THEREOF |
| MX359989B (es) * | 2012-02-17 | 2018-10-18 | Siga Tech Inc | Fármacos antivirales para el tratamiento de la infección por arenavirus. |
| WO2016022569A1 (en) | 2014-08-04 | 2016-02-11 | Blueprint Medicines Corporation | Compositions useful for treating disorders related to kit |
| WO2018013430A2 (en) * | 2016-07-12 | 2018-01-18 | Arisan Therapeutics Inc. | Heterocyclic compounds for the treatment of arenavirus infection |
-
2019
- 2019-12-02 AR ARP190103517A patent/AR117228A1/es unknown
- 2019-12-03 JP JP2021525159A patent/JP7675009B2/ja active Active
- 2019-12-03 KR KR1020217017726A patent/KR20210106997A/ko not_active Ceased
- 2019-12-03 CN CN201980080594.2A patent/CN113329750B/zh active Active
- 2019-12-03 MX MX2021005234A patent/MX2021005234A/es unknown
- 2019-12-03 WO PCT/US2019/064223 patent/WO2020117794A1/en not_active Ceased
- 2019-12-03 EP EP19892030.8A patent/EP3890731A4/en active Pending
- 2019-12-03 EA EA202191001A patent/EA202191001A1/ru unknown
- 2019-12-03 AU AU2019393784A patent/AU2019393784B2/en active Active
- 2019-12-03 BR BR112021010909-9A patent/BR112021010909A2/pt unknown
-
2021
- 2021-05-04 MX MX2024013042A patent/MX2024013042A/es unknown
Also Published As
| Publication number | Publication date |
|---|---|
| CN113329750A (zh) | 2021-08-31 |
| MX2024013042A (es) | 2024-12-06 |
| WO2020117794A1 (en) | 2020-06-11 |
| CA3118765A1 (en) | 2020-06-11 |
| CN113329750B (zh) | 2025-10-17 |
| AU2019393784B2 (en) | 2025-06-12 |
| KR20210106997A (ko) | 2021-08-31 |
| MX2021005234A (es) | 2021-08-11 |
| EP3890731A1 (en) | 2021-10-13 |
| JP7675009B2 (ja) | 2025-05-12 |
| EP3890731A4 (en) | 2022-08-17 |
| BR112021010909A2 (pt) | 2021-08-24 |
| JP2022509763A (ja) | 2022-01-24 |
| AU2019393784A1 (en) | 2021-05-27 |
| EA202191001A1 (ru) | 2021-08-16 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| AR108710A1 (es) | Compuestos modulares de fxr (nr1h4) | |
| PE20230376A1 (es) | Compuestos moduladores de la diacilglicerol quinasa | |
| AR117228A1 (es) | DERIVADOS DE PIRAZOLO[1,2-a]PIRIDINA, 1H-BENZO[d][1,2,3]TRIAZOL, IMIDAZOPIRIMIDINA Y BENCIMIDAZOL PARA USAR EN EL TRATAMIENTO DE LA INFECCIÓN POR ARENAVIRUS | |
| AR127309A2 (es) | Derivados de piridazinona | |
| AR095430A1 (es) | Compuestos de pirimidina y piridina y su uso como inhibidores de la actividad de fgfr | |
| AR114793A1 (es) | Moduladores de enzimas modificadoras de metilo, composiciones y usos de los mismos | |
| AR110405A1 (es) | Compuestos | |
| AR119657A1 (es) | Compuestos de pirimidina y composiciones farmacéuticas para prevenir o tratar cánceres que incluyen los mismos | |
| AR121777A1 (es) | Derivados de diamina macrocíclica como inhibidores de ent para el tratamiento de cánceres, y combinación de estos con antagonistas del receptor de adenosina | |
| AR123355A1 (es) | Inhibidores de apol1 y métodos para usar los mismos | |
| AR107321A1 (es) | Compuestos antiproliferativos, y sus composiciones farmacéuticas y usos | |
| AR108175A1 (es) | Compuestos antivíricos de tiazol acetamida | |
| AR111594A1 (es) | Agentes inhibidores de la tirosina quinasa de bruton | |
| AR111814A1 (es) | Compuestos de formimidamida útiles contra microorganismos fitopatógenos | |
| PE20081113A1 (es) | Inhibidores virales policiclicos | |
| AR120556A1 (es) | Compuestos heterocíclicos como inhibidores de delta-5 desaturasa y métodos de uso | |
| AR108845A1 (es) | Derivados de [1,2,3]triazolo[4,5-d]pirimidina como moduladores del receptor cb2 | |
| AR112794A1 (es) | Compuestos heteroaromáticos sustituidos con cicloolefinas y su uso en el tratamiento de enfermedades inducidas por mutaciones idh | |
| AR108327A1 (es) | Compuestos pirimidinona fusionados sustituidos | |
| AR111826A1 (es) | Compuestos bicíclicos 5,6 fusionados y composiciones para el tratamiento de las enfermedades parasitarias | |
| AR122336A1 (es) | Compuestos heterocíclicos como inhibidores de delta-5 desaturasa y métodos de uso | |
| AR119340A1 (es) | DERIVADOS DE TIENO[3,2-b]PIRIDIN-2-CARBOXAMIDA COMO MODULADORES DEL RECEPTOR DE NMDA | |
| AR110252A1 (es) | Compuestos heterocíclicos fusionados como inhibidores de la quinasa cam | |
| AR128494A1 (es) | Compuestos heterocíclicos, composiciones de los mismos y métodos de tratamiento con los mismos | |
| AR126733A1 (es) | Inhibidores de nicotinamida ripk1 |